The Shire PLC (SHP) Rating Lowered to Hold at Liberum Capital

The Shire PLC (SHP) Rating Lowered to Hold at Liberum Capital

A number of other brokerages have also commented on SHP. JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a report on Wednesday, February 8th. Credit Suisse Group AG restated an “outperform” rating and issued a GBX 5,400 ($69.36) price target on shares of Shire PLC in a report on Wednesday, February 8th. Shore Capital restated a “buy” rating on shares of Shire PLC in a report on Friday, February 10th. Citigroup Inc restated a “buy” rating on shares of Shire PLC in a report on Friday, February 17th. Finally, Deutsche Bank AG restated a “buy” rating and issued a GBX 6,300 ($80.92) price target on shares of Shire PLC in a report on Friday, February 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the company. Shire PLC has a consensus rating of “Buy” and an average price target of GBX 6,102.27 ($78.38).

Shire PLC (LON:SHP) was downgraded by equities researchers at Liberum Capital to a “hold” rating in a research report issued to clients and investors on Thursday. They currently have a GBX 4,900 ($62.94) target price on the biopharmaceutical company’s stock, down from their prior target price of GBX 5,500 ($70.65). Liberum Capital’s price objective would indicate a potential upside of 7.60% from the stock’s previous close.

Shire PLC (LON SHP) opened at 4549.50 on Thursday. Shire PLC has a 12 month low of GBX 2,707.19 and a 12 month high of GBX 5,377.00. The firm has a 50-day moving average price of GBX 4,633.00 and a 200 day moving average price of GBX 4,652.50. The firm’s market capitalization is GBX 41.13 billion.

In related news, insider William Burns bought 136 shares of the stock in a transaction that occurred on Friday, March 31st. The shares were acquired at an average price of GBX 4,742 ($60.91) per share, with a total value of £6,449.12 ($8,284.03).

About Shire PLC Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:SHP”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Shire PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Shire PLC and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment